Search - tctmd.com

Displaying 1 - 20 of 130

Sort: Relevancy | Date

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Conference News ESC 2016

Day or Night, STEMI Patients Receive Similar Levels of Quality Care

L.A. McKeown

August 31, 2016

News Conference News ESC 2016

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

Shelley Wood

August 30, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

Presentation Fellows 2016

State-of-the-Art in ACS and STEMI: Risk Stratification and Reperfusion Strategies

Presenter: Gregg Stone

April 15, 2016

Presentation

Timing of Clopidogrel Loading in US Practice

Presenter: Gregg W. Stone

February 08, 2016

News Daily News

Symptom Duration May Be More Important Than D2B for STEMI, HORIZONS-AMI Substudy Suggests

Yael L. Maxwell

January 05, 2016

News Daily News

La Duración de los Síntomas Podría ser Más Importante que el Tiempo Puerta-Balón en el Manejo de Los Cuadros de STEMI, según un Subestudio del HORIZONS-AMI

Yael L. Maxwell

January 05, 2016

News Conference News TCT 2015

Novel Devices Present New Treatment Options for STEMI

Yael L. Maxwell

October 11, 2015

News Daily News

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

L.A. McKeown

September 21, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

Presentation

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

Presenter: Gregg W. Stone

September 15, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

Failed Trial PRomPTs Questions About Role of Peri-Infarct Pacing for Remodeling of Large MIs

L.A. McKeown

August 30, 2015

News Conference News ESC 2015

CIRCUS: Transplant Rejection Drug Fails to Reduce Infarct Size in Anterior STEMI

L.A. McKeown

August 30, 2015

News Daily News

La Aprobación de la FDA de Cangrelor Amplía las Opciones Antiplaquetarias para la PCI

Todd Neale

June 29, 2015

News Daily News

FDA 批准坎格雷洛作为 PCI 的抗血小板治疗方案

Todd Neale

June 29, 2015

Advertisement

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Day or Night, STEMI Patients Receive Similar Levels of Quality Care

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

State-of-the-Art in ACS and STEMI: Risk Stratification and Reperfusion Strategies

Timing of Clopidogrel Loading in US Practice

Symptom Duration May Be More Important Than D2B for STEMI, HORIZONS-AMI Substudy Suggests

La Duración de los Síntomas Podría ser Más Importante que el Tiempo Puerta-Balón en el Manejo de Los Cuadros de STEMI, según un Subestudio del HORIZONS-AMI

Novel Devices Present New Treatment Options for STEMI

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

Post-ESC_15 Late-Breaking Trial Webcast: MATRIX Duration, OPTIDUAL, and PLATFORM

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Failed Trial PRomPTs Questions About Role of Peri-Infarct Pacing for Remodeling of Large MIs

CIRCUS: Transplant Rejection Drug Fails to Reduce Infarct Size in Anterior STEMI

La Aprobación de la FDA de Cangrelor Amplía las Opciones Antiplaquetarias para la PCI

FDA 批准坎格雷洛作为 PCI 的抗血小板治疗方案

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content